UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) | Delaware | 27-1647271 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

Sensus Healthcare, Inc. (NASDAQ:SRTS) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Kim Sutton Golodetz - LHA, IR Joe Sardano - Chairman & CEO Michael Sardano - President & General Counsel Javier Rampolla - CFO Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright Alex Nowak - Craig-Hallum Capital Group Ben Haynor - Alliance Global Partners Operator Good afternoon and welcome to the Sensus Healthcare Third Quarter 2023 Financial Results Conference Call. All ...

PART I – Financial Information This section presents the unaudited condensed consolidated financial statements and management's discussion and analysis of Sensus Healthcare, Inc [Item 1. Condensed Consolidated Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(unaudited)) This section presents the unaudited condensed consolidated financial statements of Sensus Healthcare, Inc. for the period ended June 30, 2023, including the balance sheets, statements of income (loss), stockholders' equity, and cash flows, along with accompanying notes detailing significant accounting policies and specific financial items [Condensed Consolidated Balance Sheets (unaudited)](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets%20(unaudited)) This table presents the unaudited condensed consolidated balance sheets, detailing assets, liabilities, and stockholders' equity Financial Data (in thousands) | (in thousands) | June 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $20,053 | $25,520 | | Accounts receivable, net | $9,149 | $17,299 | | Inventories | $10,131 | $3,501 | | Total current assets | $47,392 | $53,241 | | Total assets | $52,017 | $56,735 | | **Liabilities and stockholders' equity** | | | | Total current liabilities | $5,193 | $7,697 | | Total liabilities | $6,007 | $8,666 | | Total stockholders' equity | $46,010 | $48,069 | | Total liabilities and stockholders' equity | $52,017 | $56,735 | - Total assets **decreased by $4.7 million** from **$56.7 million** at December 31, 2022, to **$52.0 million** at June 30, 2023[15](index=15&type=chunk) - Total stockholders' equity **decreased by $2.0 million** from **$48.1 million** at December 31, 2022, to **$46.0 million** at June 30, 2023[15](index=15&type=chunk) [Condensed Consolidated Statements of Income (Loss) (unaudited)](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income%20(Loss)%20(unaudited)) This table presents the unaudited condensed consolidated statements of income (loss), showing revenues, gross profit, and net income (loss) Financial Data (in thousands) | (in thousands, except shares and per share data) | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Revenues | $4,527 | $12,080 | $7,941 | $22,417 | | Gross profit | $2,619 | $8,256 | $4,241 | $15,404 | | Income (loss) from operations | $(1,127) | $4,570 | $(4,065) | $8,498 | | Net income (loss) | $(380) | $3,524 | $(2,274) | $19,586 | | Net income (loss) per share – basic | $(0.02) | $0.21 | $(0.14) | $1.19 | | Net income (loss) per share – diluted | $(0.02) | $0.21 | $(0.14) | $1.17 | - Revenues **decreased by 62.8%** for the three months ended June 30, 2023, and by **64.7%** for the six months ended June 30, 2023, compared to the prior year periods[17](index=17&type=chunk) - The Company reported a **net loss of $0.38 million** for the three months ended June 30, 2023, and **$2.27 million** for the six months ended June 30, 2023, a significant decline from net income in the prior year periods[17](index=17&type=chunk) [Condensed Consolidated Statements of Stockholders' Equity (unaudited)](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity%20(unaudited)) This table details changes in stockholders' equity, including common stock, additional paid-in capital, treasury stock, and retained earnings Financial Data (in thousands) | (in thousands, except shares) | Common Stock Shares | Common Stock Amount | Additional Paid-In Capital | Treasury Stock Shares | Treasury Stock Amount | Retained Earnings (Accumulated Deficit) | Total | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | December 31, 2022 | 16,902,761 | $169 | $45,031 | (512,342) | $(3,433) | $6,302 | $48,069 | | Stock-based compensation | - | - | 161 | - | - | - | 161 | | Exercise of stock options | 8,334 | - | 46 | - | - | - | 46 | | Forfeiture of restricted stock units | (7,500) | - | (18) | - | - | - | (18) | | Surrender of shares for tax withholding | - | - | - | (4,487) | (40) | - | (40) | | Net loss | - | - | - | - | - | (1,894) | (1,894) | | March 31, 2023 (unaudited) | 16,913,595 | $169 | $45,220 | (516,829) | $(3,473) | $4,408 | $46,324 | | Stock-based compensation | - | - | 67 | - | - | - | 67 | | Forfeiture of restricted stock units | (1,000) | - | (1) | - | - | - | (1) | | Net loss | - | - | - | - | - | (380) | (380) | | June 30, 2023 (unaudited) | 16,912,595 | $169 | $45,286 | (516,829) | $(3,473) | $4,028 | $46,010 | - Total stockholders' equity **decreased from $48.07 million** at December 31, 2022, to **$46.01 million** at June 30, 2023, primarily due to net losses incurred during the period[19](index=19&type=chunk) - Stock-based compensation **added $228 thousand** to additional paid-in capital during the six months ended June 30, 2023[19](index=19&type=chunk) [Condensed Consolidated Statements of Cash Flows (unaudited)](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows%20(unaudited)) This table presents the unaudited condensed consolidated statements of cash flows, categorizing cash movements from operating, investing, and financing activities Financial Data (in thousands) | (in thousands) | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $(5,255) | $4,978 | | Net cash provided by (used in) investing activities | $(218) | $14,911 | | Net cash provided by (used in) financing activities | $6 | $(705) | | Net increase (decrease) in cash and cash equivalents | $(5,467) | $19,184 | | Cash and cash equivalents – end of period | $20,053 | $33,703 | - Net cash used in operating activities **was $5.26 million** for the six months ended June 30, 2023, a significant change from **$4.98 million** provided in the prior year period[22](index=22&type=chunk) - Net cash used in investing activities **was $0.22 million** for the six months ended June 30, 2023, compared to **$14.91 million** provided in the prior year, which included proceeds from asset sales[22](index=22&type=chunk) [Notes to the Condensed Consolidated Financial Statements (unaudited)](index=8&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements%20(unaudited)) These notes provide detailed information on the Company's organization, significant accounting policies, and specific financial statement line items - Sensus Healthcare, Inc. is primarily a manufacturer of radiation therapy devices, operating in one segment globally[24](index=24&type=chunk) - Revenue is recognized upon transfer of control of goods or services, with service contract revenues recognized over the contract period on a straight-line basis[30](index=30&type=chunk)[32](index=32&type=chunk) Disaggregated Revenue (in thousands) | Revenue Type | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Product Revenue - recognized at a point in time | $3,524 | $10,970 | $5,993 | $20,199 | | Service Revenue - recognized at a point in time | $306 | $205 | $647 | $524 | | Service Revenue - recognized over time | $697 | $905 | $1,301 | $1,694 | | Total Revenue | $4,527 | $12,080 | $7,941 | $22,417 | - One U.S. customer accounted for **46%** and **52%** of revenue for the three and six months ended June 30, 2023, respectively, and **86%** of accounts receivable as of June 30, 2023, indicating significant customer concentration[38](index=38&type=chunk) Revenue by Geographic Region (in thousands) | Region | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | United States | $3,892 (86%) | $11,349 (94%) | $7,166 (90%) | $21,497 (96%) | | China | $300 (7%) | $711 (6%) | $430 (5%) | $890 (4%) | | Guatemala | $190 (4%) | - (0%) | $190 (2%) | - (0%) | | Ireland | $135 (3%) | - (0%) | $135 (2%) | - (0%) | | Other | $10 (0%) | $20 (0%) | $20 (0%) | $30 (0%) | | Total Revenue | $4,527 (100%) | $12,080 (100%) | $7,941 (100%) | $22,417 (100%) | - The allowance for expected credit losses on accounts receivable **decreased from $107 thousand** at December 31, 2022, to **$28 thousand** at June 30, 2023[46](index=46&type=chunk) - The Company had a revolving credit facility with Silicon Valley Bank (now First-Citizens Bank & Trust Company) with **$15 million** available borrowings at June 30, 2023, and was in compliance with covenants, with no outstanding borrowings[59](index=59&type=chunk)[61](index=61&type=chunk)[62](index=62&type=chunk) Product Warranty Liability (in thousands) | Item | Amount | | :--- | :--- | | Balance, December 31, 2022 | $403 | | Warranties accrued during the period | $281 | | Payments on warranty claims | $(305) | | Balance, June 30, 2023 | $379 | - The Company leases its headquarters office under an operating lease expiring in September 2027, with a weighted-average remaining lease term of **4.25 years** and a weighted-average discount rate of **5%**[65](index=65&type=chunk)[67](index=67&type=chunk) - Purchases from the primary contract manufacturer totaled **$1.2 million** and **$7.9 million** for the three and six months ended June 30, 2023, respectively[70](index=70&type=chunk) - The Company is involved in a Department of Justice investigation regarding physician billing to Medicare for its SRT-100 product, but disputes any wrongdoing and is unable to estimate associated costs[72](index=72&type=chunk) - Unrecognized stock compensation expense **was $557 thousand** as of June 30, 2023, to be recognized over a weighted average period of **3 years**[81](index=81&type=chunk) Income Tax (Benefit) Expense (in thousands) | Period | Income Tax (Benefit) Expense | | :--- | :--- | | Three Months Ended June 30, 2023 | $(502) | | Three Months Ended June 30, 2022 | $1,070 | | Six Months Ended June 30, 2023 | $(1,303) | | Six Months Ended June 30, 2022 | $1,718 | - The effective tax rate for the three months ended June 30, 2023, **was 56.9%**, up from **23.3%** in the prior year, primarily due to an increase in non-deductible expenses relative to pretax book income[89](index=89&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=21&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on the Company's financial performance and condition, highlighting significant changes in revenues, expenses, and key balance sheet items, and discussing liquidity and capital resources [Overview](index=21&type=section&id=Overview) This section provides a general description of Sensus Healthcare's business and strategic focus - Sensus is a medical device company focused on providing non-invasive and cost-effective treatments for oncological and non-oncological skin conditions[94](index=94&type=chunk) [Segment Information](index=21&type=section&id=Segment%20Information) This section details the Company's operating segments and how they are managed - The Company manages its business globally within one reportable segment[95](index=95&type=chunk) [Results of Operations](index=21&type=section&id=Results%20of%20Operations) This section analyzes the Company's financial performance, including revenues, costs, and profitability trends Key Financial Results (in thousands) | Metric | 3 Months Ended June 30, 2023 | 3 Months Ended June 30, 2022 | Change (%) | 6 Months Ended June 30, 2023 | 6 Months Ended June 30, 2022 | Change (%) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Revenues | $4,527 | $12,080 | -62.8% | $7,941 | $22,417 | -64.7% | | Cost of sales | $1,908 | $3,824 | -50.0% | $3,700 | $7,013 | -47.1% | | Gross profit | $2,619 | $8,256 | -68.7% | $4,241 | $15,404 | -72.7% | | Income (loss) from operations | $(1,127) | $4,570 | N/A | $(4,065) | $8,498 | N/A | | Net income (loss) | $(380) | $3,524 | N/A | $(2,274) | $19,586 | N/A | - The decrease in revenues for both periods was primarily due to a lower number of SRT units sold and reduced sales to a large customer, as customers deferred purchases[97](index=97&type=chunk)[103](index=103&type=chunk) - Gross profit percentage **decreased to 57.8%** for the three months ended June 30, 2023 (from **68.6%** in 2022) and to **53.2%** for the six months ended June 30, 2023 (from **68.6%** in 2022), driven by lower unit sales and higher vendor costs[99](index=99&type=chunk)[105](index=105&type=chunk) - Selling and marketing expenses **decreased by 5.9%** for the three-month period but **increased by 27.6%** for the six-month period, mainly due to increased tradeshow and advertising expenses[100](index=100&type=chunk)[106](index=106&type=chunk) - Research and development expenses **increased by 18.8%** for the six-month period, primarily due to a project to develop a drug delivery system for an aesthetic project, expected to be completed by the end of 2023[108](index=108&type=chunk) - Other income for the six months ended June 30, 2022, included a significant **$12.8 million** gain on the sale of Sculptura assets, which was not present in 2023[109](index=109&type=chunk) [Financial Condition](index=22&type=section&id=Financial%20Condition) This section discusses key changes in the Company's balance sheet items and overall financial position - Cash and cash equivalents **decreased by $5.4 million** from December 31, 2022, to June 30, 2023[111](index=111&type=chunk) - Accounts receivable **decreased by $8.2 million**, mainly due to collections and lower sales[111](index=111&type=chunk) - Inventories **increased by $6.6 million**, primarily due to an increase in finished goods completion[112](index=112&type=chunk) - Prepaid and other assets **increased by $1.1 million**, mainly due to an increased deposit paid to a manufacturer[112](index=112&type=chunk) [Liquidity and Capital Resources](index=24&type=section&id=Liquidity%20and%20Capital%20Resources) This section evaluates the Company's ability to generate and manage cash, and its sources of funding Summary of Cash Flows (in thousands) | Activity | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | | Operating activities | $(5,255) | $4,978 | | Investing activities | $(218) | $14,911 | | Financing activities | $6 | $(705) | | Total | $(5,467) | $19,184 | - Net cash used in operating activities **was $5.3 million** for the six months ended June 30, 2023, driven by a net loss and an increase in net operating liabilities[116](index=116&type=chunk) - Net cash used in investing activities **was $0.2 million**, primarily for property and equipment acquisitions, contrasting with **$15 million** provided in the prior year from asset sales[117](index=117&type=chunk) - The Company's short-term capital needs include expenditures for expanding sales, marketing, and R&D activities[115](index=115&type=chunk) [Indebtedness](index=25&type=section&id=Indebtedness) This section outlines the Company's debt obligations and credit facilities - There were no borrowings outstanding under the Company's revolving line of credit at June 30, 2023, or December 31, 2022[114](index=114&type=chunk) [Contractual Obligations and Commitments](index=25&type=section&id=Contractual%20Obligations%20and%20Commitments) This section describes the Company's significant contractual obligations and future commitments - The Company has a contract manufacturing agreement for its SRT-100 products and is involved in legal proceedings, including a Department of Justice investigation[69](index=69&type=chunk)[72](index=72&type=chunk)[120](index=120&type=chunk) [Critical Accounting Policies and Estimates](index=25&type=section&id=Critical%20Accounting%20Policies%20and%20Estimates) This section highlights the accounting policies and estimates that require significant management judgment - The preparation of financial statements requires management to make estimates and assumptions that affect reported amounts, with actual results potentially differing significantly[121](index=121&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=25&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) This section states that the Company has no applicable quantitative and qualitative disclosures about market risk for the reporting period - The Company has no applicable quantitative and qualitative disclosures about market risk[122](index=122&type=chunk) [Item 4. Controls and Procedures](index=25&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that the Company maintained effective disclosure controls and procedures as of June 30, 2023, and reported no significant changes in internal control over financial reporting during the quarter - Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of June 30, 2023[123](index=123&type=chunk) - There were no significant changes in internal control over financial reporting during the most recently completed fiscal quarter[124](index=124&type=chunk) PART II – Other Information This section provides supplementary information including legal proceedings, risk factors, equity sales, and other disclosures [Item 1. Legal Proceedings](index=26&type=section&id=Item%201.%20Legal%20Proceedings) The Company is involved in certain legal proceedings in the ordinary course of business, as detailed in Note 7 to the financial statements - The Company is a party to certain legal proceedings in the ordinary course of business, as further described in Note 7, Commitments and Contingencies[127](index=127&type=chunk) [Item 1A. Risk Factors](index=26&type=section&id=Item%201A.%20Risk%20Factors) This section refers readers to the risk factors discussed in the Company's 2022 Annual Report on Form 10-K and subsequent quarterly reports, noting that additional unknown or immaterial risks could also adversely affect the business - Readers should consider risk factors from the 2022 Annual Report and subsequent quarterly reports[128](index=128&type=chunk) - Additional unknown or currently immaterial risks may materially adversely affect the Company's business, financial condition, or operating results[128](index=128&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=26&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The Company reported no unregistered sales of equity securities, no use of proceeds from registered securities sales, and no purchases of equity securities by the registrant or affiliated purchasers during the six months ended June 30, 2023 - There were no unregistered sales of securities during the six months ended June 30, 2023[129](index=129&type=chunk) - There was no use of proceeds from the sale of registered securities[130](index=130&type=chunk) - No purchases of equity securities by the registrant and affiliated purchasers occurred[131](index=131&type=chunk) [Item 3. Defaults Upon Senior Securities](index=26&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The Company reported no defaults upon senior securities for the period - There were no defaults upon senior securities[131](index=131&type=chunk) [Item 4. Mine Safety Disclosure](index=26&type=section&id=Item%204.%20Mine%20Safety%20Disclosure) This item is not applicable to the Company - Mine Safety Disclosure is not applicable to the Company[132](index=132&type=chunk) [Item 5. Other Information](index=26&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated any Rule 10b5-1 trading plans or non-Rule 10b5-1 trading arrangements during the three months ended June 30, 2023 - No directors or officers adopted or terminated any Rule 10b5-1 trading plans or non-Rule 10b5-1 trading arrangements during the three months ended June 30, 2023[133](index=133&type=chunk) [Item 6. Exhibits](index=27&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including employment agreements, certifications from the CEO and CFO, and Inline XBRL documents Key Exhibits Filed | Exhibit No. | Description | | :--- | :--- | | 10.1 | Employment Agreement between Sensus Healthcare, Inc. and Javier Rampolla | | 31.1 | Certification of Joseph C. Sardano, Chairman and Chief Executive Officer | | 31.2 | Certification of Javier Rampolla, Chief Financial Officer | | 32.1 | Certification of Joseph C. Sardano, Chairman and Chief Executive Officer, Pursuant to 18 U.S.C. Section 1350 | | 32.2 | Certification of Javier Rampolla, Chief Financial Officer, Pursuant to 18 U.S.C. Section 1350 | | 101.INS | Inline XBRL Instance Document | | 104 | Cover Page Interactive Data File | [Signatures](index=28&type=section&id=Signatures) This section contains the official signatures of the Company's authorized officers, certifying the report's accuracy - The report was signed by Joseph C. Sardano, Chief Executive Officer, and Javier Rampolla, Chief Financial Officer, on August 11, 2023[139](index=139&type=chunk)

Sensus Healthcare, Inc (NASDAQ:SRTS) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Kim Golodetz - IR Joseph Sardano - Chairman and CEO Michael Sardano - President and General Counsel Javier Rampolla - CFO Conference Call Participants Scott Henry - ROTH Capital Anthony Vendetti - Maxim Group Ben Haynor - Alliance Global Partners Operator Welcome to the Sensus Healthcare Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note that this event is being ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R. ...

Financial Data and Key Metrics Changes - Revenues for Q1 2023 were $3.4 million, down from $10.3 million in Q1 2022, primarily due to a lower number of SRT units sold and inflation impacts on medical practices [31][32] - Gross profit for Q1 2023 was $1.6 million, or 47.1% of revenues, compared to $7.1 million, or 68.9% of revenues in the previous year, reflecting lower unit sales and higher vendor costs [32] - Net loss for Q1 2023 was $1.9 million, or $0.12 per share, compared to net income of $16.1 million, or $0.97 per diluted share in Q1 2022, which included a $12.8 million gain on the sale of a non-core asset [36][37] Business Line Data and Key Metrics Changes - Selling and marketing expenses increased to $2.1 million in Q1 2023 from $1.2 million in Q1 2022, attributed to higher advertising expenses and increased participation in targeted tradeshows [33] - Research and development expenses rose to $1.1 million in Q1 2023 from $0.7 million in the same quarter last year, mainly due to ongoing aesthetic project expenses [35] Market Data and Key Metrics Changes - The compounded annual growth rate for SRT reimbursement has been 27% year-over-year for the past six years, while Mohs surgery has only grown at 5% during the same period [20] - The company is witnessing increased interest in its SRT systems in Asian markets, having shipped its first system to Taiwan and two systems to China in Q1 2023 [19] Company Strategy and Development Direction - The company is focusing on addressing customer hesitancies due to inflation by building inventory and prepaying for components, expecting to ship over 60 systems in 2023 [10][11] - Sensus Healthcare is expanding its presence in smaller regional conferences to connect more closely with customers and is also targeting the radiation oncology segment for skin cancer treatments [14][15][24] Management's Comments on Operating Environment and Future Outlook - Management views the current hesitancy in purchasing decisions as a temporary operating environment influenced by inflation affecting dermatology practices [10][12] - The company remains optimistic about future growth, emphasizing the importance of its proprietary Sentinel IT solutions and the potential for increased sales as the market adjusts to current economic conditions [42][48] Other Important Information - Cash and cash equivalents were $19.3 million as of March 31, 2023, down from $25.5 million at the end of 2022, while inventory increased to $6.3 million from $3.5 million [38][39] - The company is actively engaging in discussions to open new international territories, particularly in Asia and South America, with Brazil identified as a significant market opportunity [27][28] Q&A Session Summary Question: How is inflation impacting customer purchasing decisions? - Management explained that inflation is affecting consumers' discretionary spending on elective procedures, leading to hesitancy in purchasing SRT systems [53][56] Question: What were the service revenues in the quarter? - Service revenue accounted for approximately 28% of total revenue in the quarter [63] Question: What is the outlook for Q2? - Management anticipates Q2 to be another challenging quarter, but expects gradual improvement as customers adapt to the inflationary environment [71][80] Question: What is the company's strategy for international expansion? - The company is focusing on regulatory approvals and engaging the right distributors to expand into Asian markets, with specific targets on Korea and Japan [27][126] Question: What are the plans for the drug delivery system? - The drug delivery system is close to submission for FDA approval, with expectations for submission within the current quarter [99]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________ TO ____________ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1647271 (State or ot ...

Sensus Healthcare, Inc. (NASDAQ:SRTS) Q4 2022 Earnings Conference Call February 9, 2023 4:30 PM ET Company Participants Kim Golodetz - Lippert/Heilshorn & Associates Joseph Sardano - Co-Founder, Chairman & CEO Michael Sardano - President & General Counsel Javier Rampolla - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partners Alexander Nowak - Craig-Hallum Scott Henry - ROTH MKM Partners Anthony Vendetti - Maxim Group Operator Welcome to the Sensus Healthcare Fourth Quarter 2022 Earnin ...

PART I – Financial Information [Item 1. Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements) The unaudited condensed consolidated financial statements for the period ended September 30, 2022, reflect significant growth in assets, revenue, and profitability, including a $21.4 million net income driven by an asset sale [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of September 30, 2022, the balance sheet shows a 70% increase in total assets to $54.8 million, driven by a surge in cash and a substantial rise in stockholders' equity Condensed Consolidated Balance Sheet Highlights (in thousands) | Financial Metric | Sep 30, 2022 (unaudited) | Dec 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $37,577 | $14,519 | | Total current assets | $51,530 | $31,245 | | Total assets | $54,759 | $32,240 | | **Liabilities & Equity** | | | | Total current liabilities | $6,584 | $5,963 | | Total liabilities | $7,635 | $6,225 | | Retained earnings (Accumulated deficit) | $3,473 | $(17,942) | | Total stockholders' equity | $47,124 | $26,015 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The statements of operations reveal substantial revenue growth and a significant profitability turnaround for the three and nine months ended September 30, 2022, largely due to an asset sale Statement of Operations Summary (in thousands, except per share data) | Metric | Q3 2022 | Q3 2021 | 9 Months 2022 | 9 Months 2021 | | :--- | :--- | :--- | :--- | :--- | | Revenues | $9,010 | $5,525 | $31,428 | $14,017 | | Gross Profit | $5,874 | $3,201 | $21,278 | $8,132 | | Income (loss) from operations | $2,161 | $195 | $10,659 | $(1,199) | | Gain on sale of assets | - | - | $12,779 | - | | Net income (loss) | $1,829 | $195 | $21,415 | $(1,199) | | Diluted EPS | $0.11 | $0.01 | $1.28 | $(0.07) | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash and cash equivalents increased by $23.1 million for the nine months ended September 30, 2022, driven by strong operating cash flow and a significant asset sale Cash Flow Summary for the Nine Months Ended Sep 30 (in thousands) | Cash Flow Activity | 2022 | 2021 | | :--- | :--- | :--- | | Net cash provided by operating activities | $8,701 | $1,494 | | Net cash provided by investing activities | $14,851 | $167 | | Net cash used in financing activities | $(494) | $(177) | | **Net increase in cash and cash equivalents** | **$23,058** | **$1,484** | - The primary driver of investing cash flow was the **$15.0 million** received from the sale of the Sculptura assets[20](index=20&type=chunk)[51](index=51&type=chunk) - Financing activities included a **$1.0 million repurchase** of common stock and **$0.7 million in proceeds** from the exercise of stock options[20](index=20&type=chunk) [Notes to the Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) The notes provide details on accounting policies, significant events including a $15 million asset sale, revenue concentration, and an ongoing Department of Justice investigation - On February 25, 2022, the Company sold its Sculptura assets for **$15 million in cash**, recognizing a **$12.8 million gain**[51](index=51&type=chunk) - The U.S. market is the primary source of revenue, accounting for **95% of total revenue** for the nine months ended September 30, 2022, with a single U.S. customer accounting for **73% of revenue** in the same period[36](index=36&type=chunk) - The company is cooperating with a **Department of Justice investigation** into billing practices by a physician who used the company's SRT-100 device, disputing any wrongdoing and unable to estimate potential costs[67](index=67&type=chunk) - In Q1 2022, the company released a **$3.7 million valuation allowance** against its deferred tax assets, concluding it is more likely than not that these assets will be realized[79](index=79&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=18&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses strong financial performance for the first nine months of 2022, driven by increased sales, expanded gross margins, and enhanced liquidity from an asset sale [Results of Operations](index=19&type=section&id=Results%20of%20Operations) Results of operations show significant revenue growth and gross margin expansion for both the third quarter and nine months ended September 30, 2022, driven by higher unit sales Q3 2022 vs Q3 2021 Performance (in millions) | Metric | Q3 2022 | Q3 2021 | Change (%) | | :--- | :--- | :--- | :--- | | Revenues | $9.0 | $5.5 | +63.6% | | Gross Profit | $5.9 | $3.2 | +84.4% | | Gross Margin | 65.6% | 57.9% | +7.7 p.p. | | Selling & Marketing Expense | $1.8 | $1.2 | +50.0% | Nine Months 2022 vs 2021 Performance (in millions) | Metric | 9M 2022 | 9M 2021 | Change (%) | | :--- | :--- | :--- | :--- | | Revenues | $31.4 | $14.0 | +124.3% | | Gross Profit | $21.3 | $8.1 | +163.0% | | Gross Margin | 67.8% | 58.0% | +9.8 p.p. | | Selling & Marketing Expense | $4.8 | $3.5 | +37.1% | [Financial Condition, Liquidity and Capital Resources](index=21&type=section&id=Financial%20Condition%2C%20Liquidity%20and%20Capital%20Resources) The company's financial condition and liquidity significantly improved, with cash and cash equivalents increasing by $23.1 million, supported by strong operating cash flow and an asset sale - Cash and cash equivalents increased by **$23.1 million** from December 31, 2021, to September 30, 2022[103](index=103&type=chunk) - Net cash provided by operating activities was **$8.7 million** for the nine months ended September 30, 2022, compared to **$1.5 million** in the prior year period[108](index=108&type=chunk) - Net cash from investing activities was **$14.9 million**, primarily from the sale of assets[109](index=109&type=chunk) - There were **no borrowings** under the revolving line of credit as of September 30, 2022[105](index=105&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=22&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) This section is not applicable for the company as a smaller reporting company - The company stated that this section is not applicable[114](index=114&type=chunk) [Item 4. Controls and Procedures](index=22&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of September 30, 2022, with no significant changes to internal control over financial reporting - Based on an evaluation as of September 30, 2022, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were **effective**[116](index=116&type=chunk) - **No significant changes** were made to the internal control over financial reporting during the third quarter of 2022[117](index=117&type=chunk) PART II – Other Information [Item 1. Legal Proceedings](index=24&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in ordinary course legal proceedings and refers to the financial statement notes for details on commitments and contingencies, including a DOJ investigation - The company is involved in **ordinary course legal proceedings** and directs readers to the Commitments and Contingencies note in the financial statements for more details[67](index=67&type=chunk)[120](index=120&type=chunk) [Item 1A. Risk Factors](index=24&type=section&id=Item%201A.%20Risk%20Factors) No new risk factors are presented in this report, with investors directed to previously disclosed risks in the 2021 Annual Report and subsequent filings - The company refers to the risk factors disclosed in its 2021 Annual Report and subsequent quarterly reports, with **no new additions** in this filing[121](index=121&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=24&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities, no use of proceeds from registered sales, and no equity security purchases during the nine months ended September 30, 2022 - There were **no unregistered sales** of securities during the nine months ended September 30, 2022[122](index=122&type=chunk) [Item 3. Defaults Upon Senior Securities](index=24&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None[124](index=124&type=chunk) [Item 5. Other Information](index=24&type=section&id=Item%205.%20Other%20Information) No other information required to be disclosed under this item was reported - None[126](index=126&type=chunk) [Item 6. Exhibits](index=24&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including CEO and CFO certifications and Inline XBRL documents - The exhibits filed include **certifications from the CEO and CFO**, along with **XBRL data files**[127](index=127&type=chunk)

Sensus Healthcare, Inc. (NASDAQ:SRTS) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Kim Golodetz - Investor Relations Joe Sardano - Chairman and Chief Executive Officer Michael Sardano - President and General Counsel Javier Rampolla - Chief Financial Officer Conference Call Participants Scott Henry - Roth Capital Yi Chen - H.C. Wainwright Benjamin Haynor - Alliance Global Partners Anthony Vendetti - Maxim Group Operator Hello and welcome to the Sensus Healthcare Third Qua ...